Free tool
FAERS Monitor: Miacalcin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017808 or its brand name (Miacalcin, Calcitonin Salmon). Reports on generic versions are filed under their own applications.
Reports
3,123
Serious
2,212
71% of reports
Hospitalization
998
Death reported
279
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea253
- drug ineffective249
- fall221
- pain213
- arthralgia189
- dizziness184
- headache178
- back pain173
- dyspnoea164
- asthenia156
- fatigue156
- diarrhoea146
- pain in extremity146
- vomiting137
- pneumonia107
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 429 |
| 2005 | 335 |
| 2006 | 243 |
| 2007 | 144 |
| 2008 | 152 |
| 2009 | 150 |
| 2010 | 176 |
| 2011 | 176 |
| 2012 | 212 |
| 2013 | 63 |
| 2014 | 65 |
| 2015 | 142 |
| 2016 | 112 |
| 2017 | 108 |
| 2018 | 81 |
| 2019 | 91 |
| 2020 | 55 |
| 2021 | 39 |
| 2022 | 73 |
| 2023 | 81 |
| 2024 | 73 |
| 2025 | 79 |
| 2026 | 44 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,036 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| back painSignal | 173 | 5.0 | 4.3 | 558 |
| fallSignal | 221 | 4.5 | 3.9 | 602 |
| pain in extremitySignal | 146 | 3.3 | 2.8 | 240 |
| arthralgiaSignal | 189 | 3.1 | 2.7 | 266 |
| astheniaSignal | 156 | 2.8 | 2.4 | 181 |
| dizzinessSignal | 184 | 2.5 | 2.2 | 166 |
| painSignal | 213 | 2.3 | 2.1 | 166 |
| pneumoniaSignal | 107 | 2.2 | 1.8 | 72 |
| nauseaSignal | 253 | 2.2 | 1.9 | 161 |
| vomiting | 137 | 2.0 | 1.7 | 65 |
| dyspnoea | 164 | 2.0 | 1.7 | 77 |
| headache | 178 | 1.9 | 1.7 | 79 |
| diarrhoea | 146 | 1.5 | 1.3 | 27 |
| fatigue | 156 | 1.3 | 1.2 | 14 |
| drug ineffective | 249 | 1.3 | 1.1 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.